{"id":251053,"date":"2022-03-15T00:00:00","date_gmt":"2022-03-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/exinhe0002-2022-biopharma-fetal-and-neonatal-alloimmune-thrombocytopenia\/"},"modified":"2026-04-27T23:32:40","modified_gmt":"2026-04-27T23:32:40","slug":"exinhe0002-2022-biopharma-fetal-and-neonatal-alloimmune-thrombocytopenia-executive-insights-fetal-and-neonatal-alloimmune","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/exinhe0002-2022-biopharma-fetal-and-neonatal-alloimmune-thrombocytopenia-executive-insights-fetal-and-neonatal-alloimmune\/","title":{"rendered":"Fetal and Neonatal Alloimmune Thrombocytopenia &#8211; Executive Insights &#8211; Fetal and Neonatal Alloimmune Thrombocytopenia | Executive Insights | US\/EU5"},"content":{"rendered":"<p>Fetal and neonatal alloimmune thrombocytopenia (<abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr>) is a rare, alloimmune thrombocytopenic disorder affecting fetuses \/ neonates, characterized in severe cases by intracranial hemorrhage. It can result in neurological disabilities in neonates and miscarriage in some pregnancies. <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr> occurring in a woman\u2019s first pregnancy usually remains undiagnosed due to a lack of routine screening techniques. No approved therapies are available for the treatment \/ prevention of <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr>. Currently, patients are treated with off-label therapies such as <abbr title=\"Intravenous immunoglobulin\">IVIG<\/abbr>s and\/or platelet transfusions. The <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr> pipeline is sparse, with Rallybio being the only company developing prophylactic therapies for this indication. Rallybio\u2019s lead asset, the monoclonal antibody RLYB212, is being assessed in a Phase I clinical trial. Given the lack of approved therapies, unavailability of routine screening techniques, and the vulnerability of the patient population, the unmet need and market opportunities for new therapies for <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr> are clear.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What is the diagnosed incidence of <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr>, and how are patients in the markets under study treated today?<\/li>\n<li>What are the key unmet needs and areas of opportunity in the management of <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr>?<\/li>\n<li>What is the potential impact of pipeline therapies, and how will these therapies affect future market dynamics in <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr>?<\/li>\n<li>What are the key drivers and limiters of the <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr> market?<\/li>\n<li>What market access and reimbursement challenges will new therapies for <abbr title=\"fetal and neonatal alloimmune thrombocytopenia \">FNAIT<\/abbr> likely face, according to interviewed <abbr title=\"key opinion leader\">KOL<\/abbr>s?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.<\/p>\n<p><strong>GEOGRAPHY:<\/strong> United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr><\/p>\n<p><strong>PRIMARY RESEARCH<\/strong>: 13 <abbr title=\"key opinion leader\">KOL<\/abbr> interviews from November 2021 to January 2022<\/p>\n<p><strong>KEY COMPANIES COVERED:<\/strong> Rallybio<\/p>\n<p><strong>KEY DRUGS COVERED:<\/strong> Immunoglobulins, platelet transfusions, RLYB211 (NAITgam), RLYB212<\/p>\n","protected":false},"template":"","class_list":["post-251053","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hematology","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251053\/revisions"}],"predecessor-version":[{"id":283497,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251053\/revisions\/283497"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}